Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review

Jiayu Shi, Kenan Fan, Lei Yan, Zijuan Fan, Fei Li, Guishan Wang, Haifeng Liu, Peidong Liu, Hongmei Yu, Jiao Jiao Li () and Bin Wang ()
Additional contact information
Jiayu Shi: Shanxi Medical University
Kenan Fan: Shanxi Medical University
Lei Yan: Shanxi Medical University Second Affiliated Hospital
Zijuan Fan: Shanxi Medical University
Fei Li: Shanxi Medical University
Guishan Wang: Shanxi Medical University
Haifeng Liu: Shanxi Medical University Second Affiliated Hospital
Peidong Liu: Shanxi Medical University Second Affiliated Hospital
Hongmei Yu: Shanxi Medical University
Jiao Jiao Li: University of Technology Sydney
Bin Wang: Shanxi Medical University Second Affiliated Hospital

Applied Health Economics and Health Policy, 2022, vol. 20, issue 3, No 6, 370 pages

Abstract: Abstract Background and objective Osteoarthritis (OA) is a highly prevalent, disabling disease requiring chronic management that is associated with an enormous individual and societal burden. This systematic review provides a global cost-effectiveness evaluation of pharmacological therapy for the management of OA. Methods Following Center for Reviews and Dissemination (CRD) guidance, a literature search strategy was undertaken using PubMed, EMBASE, Cochrane Library, Health Technology Assessment (HTA) database, and National Health Service Economic Evaluation database (NHS EED) to identify original articles containing cost-effectiveness evaluation of OA pharmacological treatment published before 4 November 2021. Risk of bias was assessed by two independent reviewers using the Joanna Briggs Institute (JBI) critical appraisal checklist for economic evaluations. The Quality of Health Economic Studies (QHES) instrument was used to assess the reporting quality of included articles. Results Database searches identified 43 cost-effectiveness analysis studies (CEAs) on pharmacological management of OA that were conducted in 18 countries and four continents, with one study containing multiple continents. A total of four classes of drugs were assessed, including non-steroidal anti-inflammatory drugs (NSAIDs), opioid analgesics, symptomatic slow-acting drugs for osteoarthritis (SYSADOAs), and intra-articular (IA) injections. The methodological approaches of these studies showed substantial heterogeneity. The incremental cost-effectiveness ratios (ICERs) per quality-adjusted life-year (QALY) were (in 2021 US dollars) US$44.40 to US$307,013.56 for NSAIDS, US$11,984.84 to US$128,028.74 for opioids, US$10,930.17 to US$27,799.73 for SYSADOAs, and US$258.36 to US$58,447.97 for IA injections in different continents. The key drivers of cost effectiveness included medical resources, productivity, relative risks, and selected comparators. Conclusion This review showed substantial heterogeneity among studies, ranging from a finding of dominance to very high ICERs, but most studies found interventions to be cost effective based on specific ICER thresholds. Important challenges in the analysis were related to the standardization and methodological quality of studies, as well as the presentation of results.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-022-00717-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:20:y:2022:i:3:d:10.1007_s40258-022-00717-0

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-022-00717-0

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().